Lara E Coelho, Corine Chazallon, Didier Laureillard, Rodrigo Escada, Jean-Baptiste N'takpe, Isabelle Timana, Eugène Messou, Serge Eholie, Celso Khosa, Giang D Chau, Sandra Wagner Cardoso, Valdiléa G Veloso, Constance Delaugerre, Jean-Michel Molina, Beatriz Grinsztejn, Olivier Marcy, Nathalie De Castro
BACKGROUND: After antiretroviral therapy (ART) initiation, people with HIV (PWH) treated for tuberculosis (TB) may develop TB-associated immune reconstitution inflammatory syndrome (TB-IRIS). Integrase inhibitors, by providing a faster HIV-RNA decline than efavirenz, might increase the risk for this complication. We sought to assess incidence and determinants of TB-IRIS in PWH with TB on raltegravir- or efavirenz-based ART. METHODS: We conducted a secondary analysis of the Reflate TB 2 trial, which randomized ART-naive PWH on standard TB treatment, to receive raltegravir- or efavirenz-based ART...
March 2024: Open Forum Infectious Diseases